玻璃体内雷珠单抗注射治疗早产儿视网膜病变。
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
机构信息
Division of Ophthalmology, Department of Surgery, King Abdul Aziz Medical City, Riyadh, Saudi Arabia.
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia.
出版信息
Med Princ Pract. 2019;28(6):526-532. doi: 10.1159/000500310. Epub 2019 Apr 16.
OBJECTIVES
To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP).
METHODS
We conducted this retrospective case series study at King Abdul Aziz Medical City, Riyadh, Saudi Arabia. Seventy-four eyes of 37 preterm infants with ROP stage III with plus disease in zone I, posterior zone II, and aggressive posterior ROP received a single injection of 0.3 mg intravitreal ranibizumab. The favorable outcome measure was complete regression of the disease with normal vascularization of the retina of those infants.
RESULTS
The gestational age of the 37 included cases was in the range of 23-28 weeks and their body weight at birth was between 510 and 1,235 g except for one case with 2,550 g under oxygen therapy <7days with severe hypoglycemia. All eyes showed a favorable response in terms of regression of plus disease from the first day after treatment, followed by regression of stage III retinopathy. All patients developed complete vascularization over variable periods of time.
CONCLUSION
One injection of 0.3 mg intravitreal ranibizumab is effective in treating ROP stage III mainly in zones I and II.
目的
评估 0.3mg 玻璃体内注射雷珠单抗治疗早产儿视网膜病变（ROP）的疗效。
方法
本研究为沙特阿拉伯利雅得阿卜杜勒阿齐兹国王医疗城的一项回顾性病例系列研究。74 只患有 3 期 ROP 并伴有 I 区、后极部 2 区和侵袭性后部 ROP 的病变加性疾病的早产儿的 74 只眼接受了 0.3mg 玻璃体内注射雷珠单抗治疗。主要疗效指标是疾病完全消退，视网膜血管化正常。
结果
37 例纳入病例的胎龄在 23-28 周之间，出生体重在 510-1235g 之间，除了 1 例体重 2550g ，有吸氧治疗 <7 天，伴严重低血糖。所有的眼睛在治疗后的第一天就表现出了对加性疾病消退的良好反应，随后是 3 期视网膜病变的消退。所有患者在不同时间段内均出现完全血管化。
结论
0.3mg 玻璃体内注射雷珠单抗单次注射治疗 I 区和 II 区为主的 3 期 ROP 是有效的。
Zotero 插件